The diverse landscape of dermatologic toxicities of non-immune checkpoint inhibitor monoclonal antibody-based cancer therapy.
Riyad N H SeervaiSarah K FriskeEmily Y ChuRhea PhillipsKelly C NelsonAuris HuenWoo Cheal ChoLeomar Y BallesterCarlos A Torres-CabalaVictor G PrietoJonathan L CurryPublished in: Journal of cutaneous pathology (2022)
Dermatologic toxicities of non-ICI mAbs are diverse and mostly limited to inflammatory reactions. Awareness of the spectrum of the histopathologic patterns of cAE from non-ICI mAbs therapy is critical in the era of oncodermatology and oncodermatopathology.